Publications by authors named "J Fayette"

Claim this Profile
C
Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Aldéric M Fraslin, Anne Aupérin, Caroline Even, Jérôme Fayette, Esma Saada-Bouzid

Value Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
Jessica Menis, Laurent Greiller, Pierre Demontrond, Isabelle Monnet, Silvia Novello, Jerome Fayette

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Thomas Powles, Aarti Bhatia, Barbara Burtness, Takahiro Kogawa, Tomohiro Nishina, Jérome Fayette

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
Caroline Even, Kevin J Harrington, Erminia Massarelli, Simon Laban, Jérôme Fayette

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining a need for rapid response and practical guidance for recurrent and metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) management in France: A Delphi consensus.
Florian Clatot, Caroline Even, Amaury Daste, Christian Borel, Jérôme Fayette

PLoS One· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis